Show simple item record

dc.contributor.authorFlamand, Claude
dc.contributor.authorAlves Sarmento, Christelle
dc.contributor.authorEnfissi, Antoine
dc.contributor.authorBailly, Sarah
dc.contributor.authorBeillard, Emmanuel
dc.contributor.authorGaillet, Mélanie
dc.contributor.authorMichaud, Céline
dc.contributor.authorServas, Véronique
dc.contributor.authorClement, Nathalie
dc.contributor.authorPerilhou, Anaïs
dc.contributor.authorCarage, Thierry
dc.contributor.authorMusso, Didier
dc.contributor.authorCarod, Jean-François
dc.contributor.authorEustache, Stéphanie
dc.contributor.authorTourbillon, Céline
dc.contributor.authorBoizon, Elodie
dc.contributor.authorJames, Samantha
dc.contributor.authorDjossou, Félix
dc.contributor.authorSalje, Henrik
dc.contributor.authorCauchemez, Simon
dc.contributor.authorRousset, Dominique
dc.date.accessioned2021-12-22T15:05:19Z
dc.date.available2021-12-22T15:05:19Z
dc.date.issued2021-11
dc.date.submitted2020-10-12
dc.identifier.issn1935-2727
dc.identifier.otherpntd-d-20-01805
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/331686
dc.descriptionFunder: National Research Agency
dc.descriptionFunder: Regional Health Agency of French Guiana
dc.descriptionFunder: Institut Pasteur Urgence COVID-19 fundraising
dc.description.abstractBACKGROUND: While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020. METHODOLOGY/PRINCIPAL FINDINGS: A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. CONCLUSIONS/SIGNIFICANCE: The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana's young population structure.
dc.languageen
dc.publisherPublic Library of Science (PLoS)
dc.subjectResearch Article
dc.subjectBiology and life sciences
dc.subjectMedicine and health sciences
dc.subjectResearch and analysis methods
dc.titleSeroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.
dc.typeArticle
dc.date.updated2021-12-22T15:05:18Z
prism.issueIdentifier11
prism.publicationNamePLoS Negl Trop Dis
prism.volume15
dc.identifier.doi10.17863/CAM.79136
dcterms.dateAccepted2021-10-22
rioxxterms.versionofrecord10.1371/journal.pntd.0009945
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
datacite.contributor.supervisoreditor: Bowman, Natalie
dc.contributor.orcidFlamand, Claude [0000-0002-8064-445X]
dc.contributor.orcidBeillard, Emmanuel [0000-0002-2546-7614]
dc.contributor.orcidMichaud, Céline [0000-0001-5410-6298]
dc.contributor.orcidSalje, Henrik [0000-0003-3626-4254]
dc.contributor.orcidCauchemez, Simon [0000-0001-9186-4549]
dc.identifier.eissn1935-2735
pubs.funder-project-idEuropean Regional Development Fund (GY0027257)
cam.issuedOnline2021-11-12


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record